Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Mcubs Midcity Investment Cor / Equity Capital Markets

<p>MCUBS MidCity, a Japanese REIT focused on the mid-sized office assets, is raising USD 149 million via a placement to acquire three office/hotel assets in Tokyo and Osaka. In this insight, we will look at the details of the transaction and the placement. We are of the view that the transaction is a good deal for investors and would participate in the deal.</p>

MCUBS MidCity, a Japanese REIT focused on the mid-sized office assets, is raising USD 149 million via a placement to acquire three office/hotel assets in Tokyo and Osaka. In this insight, we will look at the details of the transaction and the placement. We are of the view that the transaction is a good deal for investors and would participate in the deal.

MCUBS MidCity Placement: A DPU Accretive Deal with Acquisition at Discount